Literature DB >> 16169563

Development and expression of neuropathic pain in CB1 knockout mice.

Anna Castañé1, Evelyne Célérier, Miquel Martín, Catherine Ledent, Marc Parmentier, Rafael Maldonado, Olga Valverde.   

Abstract

Neuropathic pain is a clinical manifestation characterized by the presence of spontaneous pain, allodynia and hyperalgesia. Here, we have evaluated the involvement of CB1 cannabinoid receptors in the development and expression of neuropathic pain. For this purpose, partial ligation of the sciatic nerve was performed in CB1 cannabinoid receptor knockout mice and their wild-type littermates. The development of mechanical and thermal allodynia, and thermal hyperalgesia was evaluated by using the von Frey filaments, cold-plate and plantar tests, respectively. Pre-surgical tactile and thermal withdrawal thresholds were similar in both genotypes. In wild-type mice, sciatic nerve injury led to a neuropathic pain syndrome characterized by a marked and long-lasting reduction of the paw withdrawal thresholds to mechanical and thermal stimuli. These manifestations developed similarly in mice lacking CB1 cannabinoid receptors. We have also investigated the consequences of gabapentin administration in these animals. Gabapentin (50 mg/kg/day, i.p.) induced a similar suppression of mechanical and thermal allodynia in both wild-type and CB1 knockout mice. Mild differences between genotypes were observed concerning the effect of gabapentin in the expression of thermal hyperalgesia. Taken together, our results indicate that CB1 cannabinoid receptors are not critically implicated in the development of neuropathic pain nor in the anti-allodynic and anti-hyperalgesic effects of gabapentin in this model.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16169563     DOI: 10.1016/j.neuropharm.2005.07.022

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  13 in total

1.  Methylphenidate Attenuates the Cognitive and Mood Alterations Observed in Mbnl2 Knockout Mice and Reduces Microglia Overexpression.

Authors:  Carla Ramon-Duaso; Thomas Gener; Marta Consegal; Cristina Fernández-Avilés; Juan José Gallego; Laura Castarlenas; Maurice S Swanson; Rafael de la Torre; Rafael Maldonado; M Victoria Puig; Patricia Robledo
Journal:  Cereb Cortex       Date:  2019-07-05       Impact factor: 5.357

2.  Chronic constriction injury reduces cannabinoid receptor 1 activity in the rostral anterior cingulate cortex of mice.

Authors:  Michelle R Hoot; Laura J Sim-Selley; Justin L Poklis; Rehab A Abdullah; Krista L Scoggins; Dana E Selley; William L Dewey
Journal:  Brain Res       Date:  2010-04-07       Impact factor: 3.252

Review 3.  Selective modulation of the cannabinoid type 1 (CB1) receptor as an emerging platform for the treatment of neuropathic pain.

Authors:  Samuel D Banister; Kaavya Krishna Kumar; Vineet Kumar; Brian K Kobilka; Sanjay V Malhotra
Journal:  Medchemcomm       Date:  2019-03-18       Impact factor: 3.597

Review 4.  Neuro-psychopharmacological perspective of Orphan receptors of Rhodopsin (class A) family of G protein-coupled receptors.

Authors:  Muhammad Zahid Khan; Ling He
Journal:  Psychopharmacology (Berl)       Date:  2017-03-13       Impact factor: 4.530

5.  Synthetic peripherally-restricted cannabinoid suppresses chemotherapy-induced peripheral neuropathy pain symptoms by CB1 receptor activation.

Authors:  Yatendra Mulpuri; Vincent N Marty; Joseph J Munier; Ken Mackie; Brian L Schmidt; Herbert H Seltzman; Igor Spigelman
Journal:  Neuropharmacology       Date:  2018-07-05       Impact factor: 5.250

6.  Effects of treatment with a carbon monoxide-releasing molecule and a heme oxygenase 1 inducer in the antinociceptive effects of morphine in different models of acute and chronic pain in mice.

Authors:  Arnau Hervera; Gemma Gou; Sergi Leánez; Olga Pol
Journal:  Psychopharmacology (Berl)       Date:  2013-03-13       Impact factor: 4.530

7.  Interferon-gamma is a critical modulator of CB(2) cannabinoid receptor signaling during neuropathic pain.

Authors:  Ildiko Racz; Xavier Nadal; Judith Alferink; Josep E Baños; Jennifer Rehnelt; Miquel Martín; Belén Pintado; Alfonso Gutierrez-Adan; Elena Sanguino; Nicolas Bellora; Jorge Manzanares; Andreas Zimmer; Rafael Maldonado
Journal:  J Neurosci       Date:  2008-11-12       Impact factor: 6.167

8.  Crucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic pain.

Authors:  Ildiko Racz; Xavier Nadal; Judith Alferink; Josep E Baños; Jennifer Rehnelt; Miquel Martín; Belén Pintado; Alfonso Gutierrez-Adan; Elena Sanguino; Jorge Manzanares; Andreas Zimmer; Rafael Maldonado
Journal:  J Neurosci       Date:  2008-11-12       Impact factor: 6.167

Review 9.  Treatment of Cancer Pain by Targeting Cytokines.

Authors:  I Vendrell; D Macedo; I Alho; M R Dionísio; L Costa
Journal:  Mediators Inflamm       Date:  2015-10-11       Impact factor: 4.711

10.  Role of the endocannabinoid system in the emotional manifestations of osteoarthritis pain.

Authors:  Carmen La Porta; S Andreea Bura; Jone Llorente-Onaindia; Antoni Pastor; Francisco Navarrete; María Salud García-Gutiérrez; Rafael De la Torre; Jorge Manzanares; Jordi Monfort; Rafael Maldonado
Journal:  Pain       Date:  2015-10       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.